MARKET

OBIO

OBIO

Orchestra BioMed Holdings Inc
NASDAQ
4.060
+0.150
+3.84%
After Hours: 4.150 +0.09 +2.22% 19:04 05/12 EDT
OPEN
3.900
PREV CLOSE
3.910
HIGH
4.060
LOW
3.775
VOLUME
137.92K
TURNOVER
--
52 WEEK HIGH
5.42
52 WEEK LOW
2.200
MARKET CAP
243.12M
P/E (TTM)
-3.6606
1D
5D
1M
3M
1Y
5Y
1D
Orchestra BioMed reports Q1 EPS (33c), consensus (44c)
TipRanks · 5h ago
Orchestra BioMed GAAP EPS of -$0.33 beats by $0.10, revenue of $0.11M misses by $0.05M
Seeking Alpha · 5h ago
*Orchestra BioMed Holdings 3Q Loss/Shr 33c >OBIO
Dow Jones · 5h ago
*Orchestra BioMed Holdings 3Q Rev $110,000 >OBIO
Dow Jones · 5h ago
Orchestra BioMed Hldgs Q1 EPS $(0.33) Beats $(0.41) Estimate, Sales $110.000K Miss $190.750K Estimate
Benzinga · 5h ago
Orchestra BioMed Q1 revenue falls and misses estimates
Reuters · 6h ago
BRIEF-Orchestra BioMed Q1 EPS USD -0.33
Reuters · 6h ago
Press Release: Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
Dow Jones · 6h ago
More
About OBIO
Orchestra BioMed Holdings, Inc. is a biomedical innovation company. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The Company develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.

Webull offers Orchestra Biomed Holdings Inc stock information, including NASDAQ: OBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OBIO stock methods without spending real money on the virtual paper trading platform.